ChartMill · Nov 12, 2026
Aktis Oncology (NASDAQ:AKTS) Q3 2026 Results Miss Estimates as Costs Rise
Aktis Oncology (AKTS) Q3 2026 results miss estimates as costs climb; shares fall 2.5% despite pipeline progress and cash runway into 2029.
NASDAQ · AKTS
Healthcare · Biotechnology
$16.16
Down-$0.46 (-2.77%)
Updated Nov 17, 2026, 5:24 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AKTS
1M range · 0 trading sessions · Daily adjusted prices
AKTS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AKTS.
Company
Market Activity
Research & News
AKTS research
Company profile and research snapshot.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Oppenheimer | Outperform | — |
| Aug 19, 2026 | Wedbush | Outperform | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Jul 14, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
ChartMill · Nov 12, 2026
Aktis Oncology (AKTS) Q3 2026 results miss estimates as costs climb; shares fall 2.5% despite pipeline progress and cash runway into 2029.
Yahoo · Nov 12, 2026
BOSTON (AP) — BOSTON (AP) — Aktis Oncology Inc. (AKTS) on Thursday reported a loss of $29.
Yahoo · Nov 12, 2026
Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumorsStarted first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519On track to present preliminary data for AKY-1189 in first quarter of 2027 and AKY-2519 in 2027 BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”),
Benzinga · Nov 12, 2026
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 97.18 percent increase over losses of $(19.18) per share from
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning AKTS.